• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Visby Medical triggers $25.5M contract option with BARDA to develop at-home COVID-19/flu test

Visby Medical triggers $25.5M contract option with BARDA to develop at-home COVID-19/flu test

March 25, 2022 By Sean Whooley

Visby MedicalVisby Medical announced today that it picked up $25.5 million in government funding to develop an at-home flu/COVID-19 diagnostic.

San Jose, California-based Visby executed an option in a contract from the Biomedical Advanced Research and Development Authority (BARDA) on the additional $25.5 million for the development and validation of the at-home combination test. The incremental funding follows the initial contract, which was awarded in February 2021.

Visby said it designed its developmental-stage flu-COVID-19 PCR test as a single-use, handheld, all-in-one device for detecting and distinguishing between influenza A, influenza B and SARS-CoV-2 with a single sample. It delivers results in less than 30 minutes and requires no additional equipment.

“We are honored by BARDA’s confidence in our team’s ability to develop this test and bring it to market, and we’re excited to be a part of the solution to keep kids in school, businesses operational, and minimize the spread of infectious agents,” Visby Medical Founder and CEO Adam de la Zerda said in a news release. “Our mission has always been to help patients and healthcare providers test for any infection at any time in any location. Delivering this test to patients in their homes is just one more step towards achieving that goal.”

The first phase of the contract was to garner FDA emergency use authorization for use of the test in point-of-care settings, with the new phase supporting efforts to develop and obtain FDA clearance to offer the test directly to consumers via prescription. Additionally, Visby will develop a digital companion system for interpreting test results and connect patients, providers and public health reporting systems under the contract.

“Antiviral treatments are now available for COVID and both flu strains, but they are most effective when given early in the patient’s illness,” Visby Medical CMO Dr. Gary Schoolnik said in the release. “To achieve the best outcomes, patients and physicians don’t have the luxury of waiting several days for an accurate diagnosis, and this test solves that piece of the puzzle.”

Filed Under: Business/Financial News, Diagnostics, Featured, Funding Roundup, Genomics/Molecular Diagnostics Tagged With: coronavirus, COVID-19, U.S. Biomedical Advanced Research and Development Authority (BARDA), Visby Medical

More recent news

  • Vicarious Surgical inks surgical robot collab with hospital, eyes first clinical patients
  • Bioliberty launches hub for soft-robotic wearable devices
  • Zynex submits laser pulse oximeter to FDA
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub
  • Product liability lawsuits target Medtronic, Boston Scientific spinal cord stim tech

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy